Biosimilars Europe Congress 2016

The Biosimilars Europe Congress 2016 is dedicated to latest Development in Biosimilars and the BREXIT Implications.

Topics

• Challenges faced when moving towards globalization
• Current status of Biosimliars market
• IP issues
• Opportunities in emerging markets
• Partnership
• Naming and labeling issues related to biosimilars
• Challenges and opportunities for biobetters and monoclonal antibody biosimilars
• New investment and business models
• Benefits and concerns of interchangeable and biosubstitutes and post authorization monitoring
• Clinical trials strategies and new guidelines for biosimilar clinical trials
• New solutions to demonstrate similarity and different characterization methods
• Bringing biosimilars closer to patients and healthcare professionals
• BREXIT Implications

Who should Attend

Senior attendees from:

• Clinical Development
• Biosimilar Development
• Commercial Development
• Global Strategy
• Biosimilar Analysis
• Biologics Regulation
• Regulatory Affairs
• Medical Affairs
• Regulatory Compliance
• Biobetter Development
• Biosimilar Process Development
• Biologics Development
• Follow-On Biologics
• Biosuperiors Portfolio Management
• Legal Affairs Strategic Marketing
• Strategic Planning
• Research & Development
• Commercial Affairs and Development
• Pharmacovigilance
• Market Access
• SBMP
• Market Entry